Company intelligence / Profile preview

Rise Therapeutics

Rockville, Maryland, United Statesrisetherapeutics.com ↗

Ownership: Private
Employees: ~15
Development stage: Phase 1

Overview

Currently has four products in Phase 1 clinical trials. R-3750 and R-2487 have completed dose escalation enrollment stages and are moving to dose expansion stages. R-3750 is being tested for ulcerative colitis, and R-2487 for rheumatoid arthritis. Both have shown safety profiles that allow progression to expansion enrollment.

Therapeutic areas: GastroenterologyImmunologyEndocrinologyOncologyInfectious Diseases
Modalities: Oral Immune BioModulatorsbiologicslive biotherapeutic productsimmunological-based biologicscellular-based immune therapies
Industry: Biotech

Drug pipeline

4 assets

R-3750

3 more assets in the full pipeline.

Request access →

Partnerships

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)National Institute of Health (NIH)

Beyond the preview

Go deeper on Rise Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rise Therapeutics.

Explore the full profile